Response to SMAC mimetics in patient-derived models of triple-negative breast cancer relies on RIPK1 activation
Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive breast cancer subtype with limited targeted treatment options. Second mitochondrial activator of caspases (SMAC) mimetics represent a promising therapeutic class for TNBC patients, although they have yet to be approved clinically. Screening a repository of 69 breast cancer patient-derived xenograft organoid (PDxO) lines…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
